Please check your internet connection and try again.
# Diadzein, Genistein, and Palmitoylethanolamide (PEA)
## Overview
This combination contains three compounds commonly found in dietary supplements:
* **Diadzein and Genistein:** Isoflavones derived from soybeans, known for their phytoestrogenic properties.
* **Palmitoylethanolamide (PEA):** An endogenous fatty acid amide with potential anti-inflammatory and analgesic effects.
These are typically used as dietary supplements, not FDA-approved medications. Efficacy and safety data are limited and often derived from preclinical studies or small clinical trials.
## Primary Indications
This combination is primarily marketed for:
* Pain management (e.g., neuropathic pain, osteoarthritis)
* Inflammation reduction
* Menopausal symptom relief (due to isoflavones)
## Adult Dosing
Dosing varies significantly depending on the specific product and intended use. Common ranges observed in studies and product literature include:
* **Diadzein and Genistein:** Typically dosed as a combined extract, ranging from **20 mg to 100 mg per day** of isoflavones.
* **Palmitoylethanolamide (PEA):** Commonly dosed between **300 mg to 1200 mg per day**, often divided into two or three doses.
Specific formulations may combine these ingredients in various ratios. Exact dosing depends on the product manufacturer's recommendations and the clinical context.
## Pediatric Dosing
There is **no established pediatric dosing** for this combination. Use in children is generally not recommended due to lack of safety and efficacy data.
## Dose Adjustments
Dose adjustments are not typically guided by standard pharmacokinetic principles for these supplements. Doses may be adjusted based on individual patient response and tolerability, guided by the product manufacturer's recommendations.
## Contraindications
* Hypersensitivity to any component of the product.
* Pregnancy and breastfeeding (due to limited safety data and potential hormonal effects of isoflavones).
* Individuals with hormone-sensitive cancers (e.g., breast, ovarian, uterine cancer) should use isoflavone-containing products with extreme caution, or avoid them, due to potential estrogenic activity.
## Adverse Effects
Adverse effects are generally mild and uncommon.
* **Diadzein and Genistein:** Gastrointestinal upset (nausea, diarrhea, bloating), allergic reactions. Potential for endocrine disruption, though clinical significance in humans at typical supplement doses is debated.
* **Palmitoylethanolamide (PEA):** Generally well-tolerated. Mild gastrointestinal upset, dizziness, or fatigue have been reported.
## Key Drug Interactions
* **Hormone Replacement Therapy (HRT):** Potential additive estrogenic effects with isoflavones.
* **Tamoxifen:** Isoflavones may interact with estrogen receptors and potentially affect tamoxifen efficacy.
* **Thyroid medications:** Soy isoflavones may interfere with thyroid hormone absorption or function.
* **Anticoagulants/Antiplatelets:** Limited data, but theoretically, some compounds could affect clotting.
## Monitoring
* Monitor for signs of gastrointestinal upset or allergic reactions.
* For individuals with hormone-sensitive conditions, monitor for any perceived changes.
* Assess for efficacy in pain or inflammation management.
## Clinical Pearls
* These are dietary supplements; quality and purity can vary widely between manufacturers.
* Efficacy is often based on limited or conflicting evidence.
* Due to the potential hormonal effects of diadzein and genistein, caution is advised in patients with estrogen-sensitive conditions.
* PEA's mechanism is thought to involve modulating the endocannabinoid system and mast cell degranulation, contributing to its anti-inflammatory and analgesic effects.
***
*Disclaimer: This information is intended for clinical decision support and does not replace professional medical advice. Always consult the most current prescribing information and relevant literature before making clinical decisions. Verify all drug information with the manufacturer's product literature or a reliable drug information resource.*
